nodes	percent_of_prediction	percent_of_DWPC	metapath
Moclobemide—CYP1A2—Fluorouracil—urinary bladder cancer	0.0276	0.252	CbGbCtD
Moclobemide—CYP2C9—Fluorouracil—urinary bladder cancer	0.0249	0.227	CbGbCtD
Moclobemide—CYP1A2—Etoposide—urinary bladder cancer	0.0231	0.21	CbGbCtD
Moclobemide—CYP2C9—Cisplatin—urinary bladder cancer	0.0211	0.193	CbGbCtD
Moclobemide—CYP2C19—urine—urinary bladder cancer	0.0166	0.134	CbGeAlD
Moclobemide—CYP1A2—urine—urinary bladder cancer	0.0135	0.11	CbGeAlD
Moclobemide—CYP2D6—Doxorubicin—urinary bladder cancer	0.013	0.118	CbGbCtD
Moclobemide—CYP2C9—urine—urinary bladder cancer	0.0128	0.104	CbGeAlD
Moclobemide—CYP2D6—urine—urinary bladder cancer	0.00964	0.0782	CbGeAlD
Moclobemide—MAOB—prostate gland—urinary bladder cancer	0.00683	0.0554	CbGeAlD
Moclobemide—MAOA—prostate gland—urinary bladder cancer	0.00582	0.0473	CbGeAlD
Moclobemide—MAOB—seminal vesicle—urinary bladder cancer	0.00577	0.0468	CbGeAlD
Moclobemide—MAOA—seminal vesicle—urinary bladder cancer	0.00493	0.04	CbGeAlD
Moclobemide—MAOB—renal system—urinary bladder cancer	0.00465	0.0377	CbGeAlD
Moclobemide—MAOB—urethra—urinary bladder cancer	0.00457	0.0371	CbGeAlD
Moclobemide—MAOA—renal system—urinary bladder cancer	0.00397	0.0322	CbGeAlD
Moclobemide—MAOA—urethra—urinary bladder cancer	0.0039	0.0316	CbGeAlD
Moclobemide—MAOB—female reproductive system—urinary bladder cancer	0.00373	0.0302	CbGeAlD
Moclobemide—Bezafibrate—PPARG—urinary bladder cancer	0.00341	1	CrCbGaD
Moclobemide—MAOB—vagina—urinary bladder cancer	0.00337	0.0273	CbGeAlD
Moclobemide—CYP1A2—renal system—urinary bladder cancer	0.00331	0.0269	CbGeAlD
Moclobemide—MAOA—female reproductive system—urinary bladder cancer	0.00318	0.0258	CbGeAlD
Moclobemide—CYP2C19—vagina—urinary bladder cancer	0.00294	0.0238	CbGeAlD
Moclobemide—MAOA—vagina—urinary bladder cancer	0.00288	0.0233	CbGeAlD
Moclobemide—CYP2C9—female reproductive system—urinary bladder cancer	0.00252	0.0204	CbGeAlD
Moclobemide—CYP2D6—renal system—urinary bladder cancer	0.00236	0.0191	CbGeAlD
Moclobemide—MAOB—lymph node—urinary bladder cancer	0.00218	0.0177	CbGeAlD
Moclobemide—CYP2D6—female reproductive system—urinary bladder cancer	0.00189	0.0153	CbGeAlD
Moclobemide—MAOA—lymph node—urinary bladder cancer	0.00186	0.0151	CbGeAlD
Moclobemide—Anxiety—Cisplatin—urinary bladder cancer	0.00104	0.00203	CcSEcCtD
Moclobemide—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00103	0.00202	CcSEcCtD
Moclobemide—Hot flush—Doxorubicin—urinary bladder cancer	0.00103	0.00202	CcSEcCtD
Moclobemide—Discomfort—Cisplatin—urinary bladder cancer	0.00103	0.00201	CcSEcCtD
Moclobemide—Tachycardia—Fluorouracil—urinary bladder cancer	0.00103	0.00201	CcSEcCtD
Moclobemide—Migraine—Epirubicin—urinary bladder cancer	0.00103	0.00201	CcSEcCtD
Moclobemide—Menopausal symptoms—Doxorubicin—urinary bladder cancer	0.00102	0.002	CcSEcCtD
Moclobemide—Urticaria—Thiotepa—urinary bladder cancer	0.00101	0.00198	CcSEcCtD
Moclobemide—Malaise—Etoposide—urinary bladder cancer	0.00101	0.00198	CcSEcCtD
Moclobemide—Abdominal pain—Thiotepa—urinary bladder cancer	0.00101	0.00197	CcSEcCtD
Moclobemide—Hypotension—Gemcitabine—urinary bladder cancer	0.001	0.00196	CcSEcCtD
Moclobemide—Loss of consciousness—Etoposide—urinary bladder cancer	0.000984	0.00193	CcSEcCtD
Moclobemide—Hypotension—Fluorouracil—urinary bladder cancer	0.000983	0.00192	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000975	0.00191	CcSEcCtD
Moclobemide—Tachycardia—Cisplatin—urinary bladder cancer	0.000974	0.0019	CcSEcCtD
Moclobemide—Insomnia—Gemcitabine—urinary bladder cancer	0.000968	0.00189	CcSEcCtD
Moclobemide—Hypertension—Etoposide—urinary bladder cancer	0.000967	0.00189	CcSEcCtD
Moclobemide—Osteoarthritis—Doxorubicin—urinary bladder cancer	0.000965	0.00189	CcSEcCtD
Moclobemide—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000965	0.00189	CcSEcCtD
Moclobemide—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000961	0.00188	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000959	0.00188	CcSEcCtD
Moclobemide—Dry skin—Epirubicin—urinary bladder cancer	0.000956	0.00187	CcSEcCtD
Moclobemide—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000954	0.00187	CcSEcCtD
Moclobemide—Chest pain—Etoposide—urinary bladder cancer	0.000954	0.00187	CcSEcCtD
Moclobemide—Insomnia—Fluorouracil—urinary bladder cancer	0.000952	0.00186	CcSEcCtD
Moclobemide—Somnolence—Gemcitabine—urinary bladder cancer	0.000952	0.00186	CcSEcCtD
Moclobemide—Migraine—Doxorubicin—urinary bladder cancer	0.000949	0.00186	CcSEcCtD
Moclobemide—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000945	0.00185	CcSEcCtD
Moclobemide—Discomfort—Etoposide—urinary bladder cancer	0.000942	0.00184	CcSEcCtD
Moclobemide—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000938	0.00184	CcSEcCtD
Moclobemide—Somnolence—Fluorouracil—urinary bladder cancer	0.000936	0.00183	CcSEcCtD
Moclobemide—Hypotension—Cisplatin—urinary bladder cancer	0.000932	0.00182	CcSEcCtD
Moclobemide—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000931	0.00182	CcSEcCtD
Moclobemide—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000926	0.00181	CcSEcCtD
Moclobemide—Fatigue—Gemcitabine—urinary bladder cancer	0.000923	0.00181	CcSEcCtD
Moclobemide—Gastritis—Epirubicin—urinary bladder cancer	0.000923	0.0018	CcSEcCtD
Moclobemide—Confusional state—Etoposide—urinary bladder cancer	0.000922	0.0018	CcSEcCtD
Moclobemide—Constipation—Gemcitabine—urinary bladder cancer	0.000915	0.00179	CcSEcCtD
Moclobemide—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000915	0.00179	CcSEcCtD
Moclobemide—Asthenia—Thiotepa—urinary bladder cancer	0.000913	0.00179	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000909	0.00178	CcSEcCtD
Moclobemide—Abdominal distension—Epirubicin—urinary bladder cancer	0.000907	0.00177	CcSEcCtD
Moclobemide—Dysuria—Methotrexate—urinary bladder cancer	0.0009	0.00176	CcSEcCtD
Moclobemide—Pruritus—Thiotepa—urinary bladder cancer	0.0009	0.00176	CcSEcCtD
Moclobemide—Paraesthesia—Cisplatin—urinary bladder cancer	0.000896	0.00175	CcSEcCtD
Moclobemide—Tachycardia—Etoposide—urinary bladder cancer	0.000892	0.00175	CcSEcCtD
Moclobemide—Dyspnoea—Cisplatin—urinary bladder cancer	0.00089	0.00174	CcSEcCtD
Moclobemide—Dry skin—Doxorubicin—urinary bladder cancer	0.000884	0.00173	CcSEcCtD
Moclobemide—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000884	0.00173	CcSEcCtD
Moclobemide—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000882	0.00173	CcSEcCtD
Moclobemide—Angina pectoris—Epirubicin—urinary bladder cancer	0.000878	0.00172	CcSEcCtD
Moclobemide—Diarrhoea—Thiotepa—urinary bladder cancer	0.000871	0.0017	CcSEcCtD
Moclobemide—Decreased appetite—Cisplatin—urinary bladder cancer	0.000867	0.0017	CcSEcCtD
Moclobemide—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000867	0.0017	CcSEcCtD
Moclobemide—Drowsiness—Methotrexate—urinary bladder cancer	0.000858	0.00168	CcSEcCtD
Moclobemide—Hypotension—Etoposide—urinary bladder cancer	0.000854	0.00167	CcSEcCtD
Moclobemide—Gastritis—Doxorubicin—urinary bladder cancer	0.000854	0.00167	CcSEcCtD
Moclobemide—Dysuria—Epirubicin—urinary bladder cancer	0.000843	0.00165	CcSEcCtD
Moclobemide—Dizziness—Thiotepa—urinary bladder cancer	0.000841	0.00165	CcSEcCtD
Moclobemide—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000839	0.00164	CcSEcCtD
Moclobemide—Stomatitis—Methotrexate—urinary bladder cancer	0.000837	0.00164	CcSEcCtD
Moclobemide—Urticaria—Fluorouracil—urinary bladder cancer	0.000836	0.00164	CcSEcCtD
Moclobemide—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000834	0.00163	CcSEcCtD
Moclobemide—Sweating—Methotrexate—urinary bladder cancer	0.000823	0.00161	CcSEcCtD
Moclobemide—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000822	0.00161	CcSEcCtD
Moclobemide—Paraesthesia—Etoposide—urinary bladder cancer	0.000821	0.00161	CcSEcCtD
Moclobemide—Dyspnoea—Etoposide—urinary bladder cancer	0.000815	0.00159	CcSEcCtD
Moclobemide—Somnolence—Etoposide—urinary bladder cancer	0.000813	0.00159	CcSEcCtD
Moclobemide—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000812	0.00159	CcSEcCtD
Moclobemide—Vomiting—Thiotepa—urinary bladder cancer	0.000809	0.00158	CcSEcCtD
Moclobemide—Drowsiness—Epirubicin—urinary bladder cancer	0.000803	0.00157	CcSEcCtD
Moclobemide—Rash—Thiotepa—urinary bladder cancer	0.000802	0.00157	CcSEcCtD
Moclobemide—Dermatitis—Thiotepa—urinary bladder cancer	0.000802	0.00157	CcSEcCtD
Moclobemide—Headache—Thiotepa—urinary bladder cancer	0.000797	0.00156	CcSEcCtD
Moclobemide—Decreased appetite—Etoposide—urinary bladder cancer	0.000795	0.00155	CcSEcCtD
Moclobemide—Fatigue—Etoposide—urinary bladder cancer	0.000788	0.00154	CcSEcCtD
Moclobemide—Stomatitis—Epirubicin—urinary bladder cancer	0.000783	0.00153	CcSEcCtD
Moclobemide—Constipation—Etoposide—urinary bladder cancer	0.000782	0.00153	CcSEcCtD
Moclobemide—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000781	0.00153	CcSEcCtD
Moclobemide—Dysuria—Doxorubicin—urinary bladder cancer	0.00078	0.00153	CcSEcCtD
Moclobemide—Sweating—Epirubicin—urinary bladder cancer	0.00077	0.00151	CcSEcCtD
Moclobemide—Asthenia—Gemcitabine—urinary bladder cancer	0.000768	0.0015	CcSEcCtD
Moclobemide—Pruritus—Gemcitabine—urinary bladder cancer	0.000757	0.00148	CcSEcCtD
Moclobemide—Nausea—Thiotepa—urinary bladder cancer	0.000756	0.00148	CcSEcCtD
Moclobemide—Feeling abnormal—Etoposide—urinary bladder cancer	0.000753	0.00147	CcSEcCtD
Moclobemide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000747	0.00146	CcSEcCtD
Moclobemide—Pruritus—Fluorouracil—urinary bladder cancer	0.000745	0.00146	CcSEcCtD
Moclobemide—Drowsiness—Doxorubicin—urinary bladder cancer	0.000743	0.00145	CcSEcCtD
Moclobemide—Visual impairment—Methotrexate—urinary bladder cancer	0.000743	0.00145	CcSEcCtD
Moclobemide—Bradycardia—Epirubicin—urinary bladder cancer	0.000734	0.00144	CcSEcCtD
Moclobemide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000732	0.00143	CcSEcCtD
Moclobemide—Urticaria—Etoposide—urinary bladder cancer	0.000726	0.00142	CcSEcCtD
Moclobemide—Stomatitis—Doxorubicin—urinary bladder cancer	0.000725	0.00142	CcSEcCtD
Moclobemide—Abdominal pain—Etoposide—urinary bladder cancer	0.000723	0.00141	CcSEcCtD
Moclobemide—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000723	0.00141	CcSEcCtD
Moclobemide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00072	0.00141	CcSEcCtD
Moclobemide—Tinnitus—Methotrexate—urinary bladder cancer	0.000719	0.00141	CcSEcCtD
Moclobemide—Asthenia—Cisplatin—urinary bladder cancer	0.000716	0.0014	CcSEcCtD
Moclobemide—Sweating—Doxorubicin—urinary bladder cancer	0.000713	0.00139	CcSEcCtD
Moclobemide—Dizziness—Fluorouracil—urinary bladder cancer	0.000696	0.00136	CcSEcCtD
Moclobemide—Visual impairment—Epirubicin—urinary bladder cancer	0.000695	0.00136	CcSEcCtD
Moclobemide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000683	0.00134	CcSEcCtD
Moclobemide—Vomiting—Gemcitabine—urinary bladder cancer	0.000681	0.00133	CcSEcCtD
Moclobemide—Bradycardia—Doxorubicin—urinary bladder cancer	0.000679	0.00133	CcSEcCtD
Moclobemide—Rash—Gemcitabine—urinary bladder cancer	0.000675	0.00132	CcSEcCtD
Moclobemide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000674	0.00132	CcSEcCtD
Moclobemide—Tinnitus—Epirubicin—urinary bladder cancer	0.000672	0.00132	CcSEcCtD
Moclobemide—Headache—Gemcitabine—urinary bladder cancer	0.000671	0.00131	CcSEcCtD
Moclobemide—Flushing—Epirubicin—urinary bladder cancer	0.000669	0.00131	CcSEcCtD
Moclobemide—Vomiting—Fluorouracil—urinary bladder cancer	0.000669	0.00131	CcSEcCtD
Moclobemide—Rash—Fluorouracil—urinary bladder cancer	0.000664	0.0013	CcSEcCtD
Moclobemide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000663	0.0013	CcSEcCtD
Moclobemide—Headache—Fluorouracil—urinary bladder cancer	0.000659	0.00129	CcSEcCtD
Moclobemide—Dysgeusia—Methotrexate—urinary bladder cancer	0.000657	0.00129	CcSEcCtD
Moclobemide—Asthenia—Etoposide—urinary bladder cancer	0.000656	0.00128	CcSEcCtD
Moclobemide—Pruritus—Etoposide—urinary bladder cancer	0.000647	0.00127	CcSEcCtD
Moclobemide—Visual impairment—Doxorubicin—urinary bladder cancer	0.000643	0.00126	CcSEcCtD
Moclobemide—Nausea—Gemcitabine—urinary bladder cancer	0.000636	0.00124	CcSEcCtD
Moclobemide—Vomiting—Cisplatin—urinary bladder cancer	0.000634	0.00124	CcSEcCtD
Moclobemide—Vision blurred—Methotrexate—urinary bladder cancer	0.000632	0.00124	CcSEcCtD
Moclobemide—Rash—Cisplatin—urinary bladder cancer	0.000629	0.00123	CcSEcCtD
Moclobemide—Dermatitis—Cisplatin—urinary bladder cancer	0.000629	0.00123	CcSEcCtD
Moclobemide—Diarrhoea—Etoposide—urinary bladder cancer	0.000625	0.00122	CcSEcCtD
Moclobemide—Nausea—Fluorouracil—urinary bladder cancer	0.000625	0.00122	CcSEcCtD
Moclobemide—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000622	0.00122	CcSEcCtD
Moclobemide—Tinnitus—Doxorubicin—urinary bladder cancer	0.000622	0.00122	CcSEcCtD
Moclobemide—Flushing—Doxorubicin—urinary bladder cancer	0.000619	0.00121	CcSEcCtD
Moclobemide—Flatulence—Epirubicin—urinary bladder cancer	0.000619	0.00121	CcSEcCtD
Moclobemide—Tension—Epirubicin—urinary bladder cancer	0.000616	0.00121	CcSEcCtD
Moclobemide—Dysgeusia—Epirubicin—urinary bladder cancer	0.000615	0.0012	CcSEcCtD
Moclobemide—Nervousness—Epirubicin—urinary bladder cancer	0.00061	0.00119	CcSEcCtD
Moclobemide—Malaise—Methotrexate—urinary bladder cancer	0.000605	0.00118	CcSEcCtD
Moclobemide—Dizziness—Etoposide—urinary bladder cancer	0.000604	0.00118	CcSEcCtD
Moclobemide—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000601	0.00238	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.0006	0.00237	CbGpPWpGaD
Moclobemide—Nausea—Cisplatin—urinary bladder cancer	0.000593	0.00116	CcSEcCtD
Moclobemide—Vision blurred—Epirubicin—urinary bladder cancer	0.000592	0.00116	CcSEcCtD
Moclobemide—MAOA—Biological oxidations—GSTP1—urinary bladder cancer	0.000589	0.00233	CbGpPWpGaD
Moclobemide—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000583	0.00114	CcSEcCtD
Moclobemide—Vomiting—Etoposide—urinary bladder cancer	0.000581	0.00114	CcSEcCtD
Moclobemide—Agitation—Epirubicin—urinary bladder cancer	0.000577	0.00113	CcSEcCtD
Moclobemide—Rash—Etoposide—urinary bladder cancer	0.000576	0.00113	CcSEcCtD
Moclobemide—Dermatitis—Etoposide—urinary bladder cancer	0.000576	0.00113	CcSEcCtD
Moclobemide—MAOB—Metabolism—GSTZ1—urinary bladder cancer	0.000575	0.00228	CbGpPWpGaD
Moclobemide—Headache—Etoposide—urinary bladder cancer	0.000573	0.00112	CcSEcCtD
Moclobemide—Flatulence—Doxorubicin—urinary bladder cancer	0.000572	0.00112	CcSEcCtD
Moclobemide—Chest pain—Methotrexate—urinary bladder cancer	0.000571	0.00112	CcSEcCtD
Moclobemide—Myalgia—Methotrexate—urinary bladder cancer	0.000571	0.00112	CcSEcCtD
Moclobemide—Tension—Doxorubicin—urinary bladder cancer	0.00057	0.00112	CcSEcCtD
Moclobemide—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000569	0.00111	CcSEcCtD
Moclobemide—Malaise—Epirubicin—urinary bladder cancer	0.000566	0.00111	CcSEcCtD
Moclobemide—Discomfort—Methotrexate—urinary bladder cancer	0.000564	0.0011	CcSEcCtD
Moclobemide—Nervousness—Doxorubicin—urinary bladder cancer	0.000564	0.0011	CcSEcCtD
Moclobemide—Syncope—Epirubicin—urinary bladder cancer	0.000563	0.0011	CcSEcCtD
Moclobemide—Palpitations—Epirubicin—urinary bladder cancer	0.000555	0.00109	CcSEcCtD
Moclobemide—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000553	0.00219	CbGpPWpGaD
Moclobemide—Confusional state—Methotrexate—urinary bladder cancer	0.000552	0.00108	CcSEcCtD
Moclobemide—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000552	0.00108	CcSEcCtD
Moclobemide—Vision blurred—Doxorubicin—urinary bladder cancer	0.000547	0.00107	CcSEcCtD
Moclobemide—MAOB—Metabolism—GSTO2—urinary bladder cancer	0.000545	0.00216	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—NAT1—urinary bladder cancer	0.000545	0.00216	CbGpPWpGaD
Moclobemide—Nausea—Etoposide—urinary bladder cancer	0.000543	0.00106	CcSEcCtD
Moclobemide—Hypertension—Epirubicin—urinary bladder cancer	0.000542	0.00106	CcSEcCtD
Moclobemide—MAOA—Biological oxidations—GSTM1—urinary bladder cancer	0.000542	0.00215	CbGpPWpGaD
Moclobemide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000539	0.00105	CcSEcCtD
Moclobemide—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.000536	0.00212	CbGpPWpGaD
Moclobemide—Myalgia—Epirubicin—urinary bladder cancer	0.000535	0.00105	CcSEcCtD
Moclobemide—Chest pain—Epirubicin—urinary bladder cancer	0.000535	0.00105	CcSEcCtD
Moclobemide—Agitation—Doxorubicin—urinary bladder cancer	0.000534	0.00104	CcSEcCtD
Moclobemide—Anxiety—Epirubicin—urinary bladder cancer	0.000533	0.00104	CcSEcCtD
Moclobemide—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000529	0.00104	CcSEcCtD
Moclobemide—Discomfort—Epirubicin—urinary bladder cancer	0.000528	0.00103	CcSEcCtD
Moclobemide—Malaise—Doxorubicin—urinary bladder cancer	0.000524	0.00102	CcSEcCtD
Moclobemide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000524	0.00207	CbGpPWpGaD
Moclobemide—Dry mouth—Epirubicin—urinary bladder cancer	0.000523	0.00102	CcSEcCtD
Moclobemide—Syncope—Doxorubicin—urinary bladder cancer	0.000521	0.00102	CcSEcCtD
Moclobemide—CYP2C19—Biological oxidations—NAT2—urinary bladder cancer	0.000519	0.00206	CbGpPWpGaD
Moclobemide—Confusional state—Epirubicin—urinary bladder cancer	0.000517	0.00101	CcSEcCtD
Moclobemide—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000514	0.00204	CbGpPWpGaD
Moclobemide—Palpitations—Doxorubicin—urinary bladder cancer	0.000513	0.001	CcSEcCtD
Moclobemide—CYP2C19—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000512	0.00203	CbGpPWpGaD
Moclobemide—Hypotension—Methotrexate—urinary bladder cancer	0.000512	0.001	CcSEcCtD
Moclobemide—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000511	0.000999	CcSEcCtD
Moclobemide—Shock—Epirubicin—urinary bladder cancer	0.000504	0.000986	CcSEcCtD
Moclobemide—Hypertension—Doxorubicin—urinary bladder cancer	0.000502	0.000981	CcSEcCtD
Moclobemide—Tachycardia—Epirubicin—urinary bladder cancer	0.0005	0.000978	CcSEcCtD
Moclobemide—MAOB—Metabolism—UGT2B7—urinary bladder cancer	0.000499	0.00198	CbGpPWpGaD
Moclobemide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000499	0.000976	CcSEcCtD
Moclobemide—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000495	0.000969	CcSEcCtD
Moclobemide—Insomnia—Methotrexate—urinary bladder cancer	0.000495	0.000969	CcSEcCtD
Moclobemide—Myalgia—Doxorubicin—urinary bladder cancer	0.000495	0.000967	CcSEcCtD
Moclobemide—Chest pain—Doxorubicin—urinary bladder cancer	0.000495	0.000967	CcSEcCtD
Moclobemide—Anxiety—Doxorubicin—urinary bladder cancer	0.000493	0.000964	CcSEcCtD
Moclobemide—Paraesthesia—Methotrexate—urinary bladder cancer	0.000492	0.000962	CcSEcCtD
Moclobemide—Discomfort—Doxorubicin—urinary bladder cancer	0.000489	0.000956	CcSEcCtD
Moclobemide—Dyspnoea—Methotrexate—urinary bladder cancer	0.000488	0.000955	CcSEcCtD
Moclobemide—Somnolence—Methotrexate—urinary bladder cancer	0.000487	0.000952	CcSEcCtD
Moclobemide—Dry mouth—Doxorubicin—urinary bladder cancer	0.000484	0.000946	CcSEcCtD
Moclobemide—Dyspepsia—Methotrexate—urinary bladder cancer	0.000482	0.000943	CcSEcCtD
Moclobemide—Hypotension—Epirubicin—urinary bladder cancer	0.000479	0.000937	CcSEcCtD
Moclobemide—Confusional state—Doxorubicin—urinary bladder cancer	0.000478	0.000935	CcSEcCtD
Moclobemide—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000477	0.00189	CbGpPWpGaD
Moclobemide—Decreased appetite—Methotrexate—urinary bladder cancer	0.000476	0.000931	CcSEcCtD
Moclobemide—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000473	0.00187	CbGpPWpGaD
Moclobemide—Fatigue—Methotrexate—urinary bladder cancer	0.000472	0.000923	CcSEcCtD
Moclobemide—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000471	0.00186	CbGpPWpGaD
Moclobemide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000467	0.000913	CcSEcCtD
Moclobemide—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000467	0.00185	CbGpPWpGaD
Moclobemide—Shock—Doxorubicin—urinary bladder cancer	0.000466	0.000912	CcSEcCtD
Moclobemide—Insomnia—Epirubicin—urinary bladder cancer	0.000463	0.000907	CcSEcCtD
Moclobemide—Tachycardia—Doxorubicin—urinary bladder cancer	0.000463	0.000905	CcSEcCtD
Moclobemide—Paraesthesia—Epirubicin—urinary bladder cancer	0.00046	0.0009	CcSEcCtD
Moclobemide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000458	0.000897	CcSEcCtD
Moclobemide—Dyspnoea—Epirubicin—urinary bladder cancer	0.000457	0.000894	CcSEcCtD
Moclobemide—Somnolence—Epirubicin—urinary bladder cancer	0.000456	0.000891	CcSEcCtD
Moclobemide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000451	0.000883	CcSEcCtD
Moclobemide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000451	0.000882	CcSEcCtD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000451	0.00179	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CYP4B1—urinary bladder cancer	0.000449	0.00178	CbGpPWpGaD
Moclobemide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000448	0.000876	CcSEcCtD
Moclobemide—Decreased appetite—Epirubicin—urinary bladder cancer	0.000445	0.000871	CcSEcCtD
Moclobemide—Hypotension—Doxorubicin—urinary bladder cancer	0.000443	0.000867	CcSEcCtD
Moclobemide—Fatigue—Epirubicin—urinary bladder cancer	0.000442	0.000864	CcSEcCtD
Moclobemide—Constipation—Epirubicin—urinary bladder cancer	0.000438	0.000857	CcSEcCtD
Moclobemide—Urticaria—Methotrexate—urinary bladder cancer	0.000435	0.000851	CcSEcCtD
Moclobemide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000433	0.000847	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000432	0.000845	CcSEcCtD
Moclobemide—Insomnia—Doxorubicin—urinary bladder cancer	0.000429	0.000839	CcSEcCtD
Moclobemide—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000426	0.000833	CcSEcCtD
Moclobemide—MAOB—Metabolism—SLC19A1—urinary bladder cancer	0.000424	0.00168	CbGpPWpGaD
Moclobemide—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000423	0.000827	CcSEcCtD
Moclobemide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000422	0.000826	CcSEcCtD
Moclobemide—Somnolence—Doxorubicin—urinary bladder cancer	0.000421	0.000824	CcSEcCtD
Moclobemide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000419	0.00082	CcSEcCtD
Moclobemide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000417	0.000816	CcSEcCtD
Moclobemide—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	0.000415	0.00164	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PRSS3—urinary bladder cancer	0.000413	0.00164	CbGpPWpGaD
Moclobemide—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000412	0.000806	CcSEcCtD
Moclobemide—Fatigue—Doxorubicin—urinary bladder cancer	0.000409	0.0008	CcSEcCtD
Moclobemide—Urticaria—Epirubicin—urinary bladder cancer	0.000407	0.000796	CcSEcCtD
Moclobemide—Constipation—Doxorubicin—urinary bladder cancer	0.000405	0.000793	CcSEcCtD
Moclobemide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000405	0.000792	CcSEcCtD
Moclobemide—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000404	0.0016	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000403	0.0016	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	0.000402	0.00159	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000399	0.00158	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000394	0.00156	CbGpPWpGaD
Moclobemide—Asthenia—Methotrexate—urinary bladder cancer	0.000393	0.000768	CcSEcCtD
Moclobemide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000391	0.000764	CcSEcCtD
Moclobemide—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000388	0.00154	CbGpPWpGaD
Moclobemide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000388	0.000758	CcSEcCtD
Moclobemide—Pruritus—Methotrexate—urinary bladder cancer	0.000387	0.000758	CcSEcCtD
Moclobemide—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000382	0.00151	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000378	0.0015	CbGpPWpGaD
Moclobemide—Urticaria—Doxorubicin—urinary bladder cancer	0.000377	0.000737	CcSEcCtD
Moclobemide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000375	0.000733	CcSEcCtD
Moclobemide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000375	0.000733	CcSEcCtD
Moclobemide—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000372	0.00147	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.00037	0.00147	CbGpPWpGaD
Moclobemide—Asthenia—Epirubicin—urinary bladder cancer	0.000368	0.000719	CcSEcCtD
Moclobemide—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000367	0.00145	CbGpPWpGaD
Moclobemide—Pruritus—Epirubicin—urinary bladder cancer	0.000363	0.000709	CcSEcCtD
Moclobemide—Dizziness—Methotrexate—urinary bladder cancer	0.000362	0.000708	CcSEcCtD
Moclobemide—MAOA—Metabolism—GSTZ1—urinary bladder cancer	0.000361	0.00143	CbGpPWpGaD
Moclobemide—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000354	0.0014	CbGpPWpGaD
Moclobemide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000351	0.000686	CcSEcCtD
Moclobemide—Vomiting—Methotrexate—urinary bladder cancer	0.000348	0.000681	CcSEcCtD
Moclobemide—Rash—Methotrexate—urinary bladder cancer	0.000345	0.000675	CcSEcCtD
Moclobemide—Dermatitis—Methotrexate—urinary bladder cancer	0.000345	0.000675	CcSEcCtD
Moclobemide—Headache—Methotrexate—urinary bladder cancer	0.000343	0.000671	CcSEcCtD
Moclobemide—MAOA—Metabolism—GSTO2—urinary bladder cancer	0.000342	0.00136	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—NAT1—urinary bladder cancer	0.000342	0.00136	CbGpPWpGaD
Moclobemide—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000341	0.00135	CbGpPWpGaD
Moclobemide—Asthenia—Doxorubicin—urinary bladder cancer	0.00034	0.000665	CcSEcCtD
Moclobemide—Dizziness—Epirubicin—urinary bladder cancer	0.000339	0.000663	CcSEcCtD
Moclobemide—Pruritus—Doxorubicin—urinary bladder cancer	0.000335	0.000656	CcSEcCtD
Moclobemide—MAOB—Metabolism—TYMP—urinary bladder cancer	0.00033	0.00131	CbGpPWpGaD
Moclobemide—Vomiting—Epirubicin—urinary bladder cancer	0.000326	0.000637	CcSEcCtD
Moclobemide—Nausea—Methotrexate—urinary bladder cancer	0.000325	0.000636	CcSEcCtD
Moclobemide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000324	0.000635	CcSEcCtD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000323	0.00128	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000323	0.00128	CbGpPWpGaD
Moclobemide—Rash—Epirubicin—urinary bladder cancer	0.000323	0.000632	CcSEcCtD
Moclobemide—Dermatitis—Epirubicin—urinary bladder cancer	0.000323	0.000631	CcSEcCtD
Moclobemide—Headache—Epirubicin—urinary bladder cancer	0.000321	0.000628	CcSEcCtD
Moclobemide—MAOA—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.00032	0.00127	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000314	0.00124	CbGpPWpGaD
Moclobemide—Dizziness—Doxorubicin—urinary bladder cancer	0.000314	0.000613	CcSEcCtD
Moclobemide—MAOA—Metabolism—UGT2B7—urinary bladder cancer	0.000313	0.00124	CbGpPWpGaD
Moclobemide—Nausea—Epirubicin—urinary bladder cancer	0.000304	0.000595	CcSEcCtD
Moclobemide—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000303	0.0012	CbGpPWpGaD
Moclobemide—Vomiting—Doxorubicin—urinary bladder cancer	0.000301	0.00059	CcSEcCtD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.0003	0.00119	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.0003	0.00119	CbGpPWpGaD
Moclobemide—Rash—Doxorubicin—urinary bladder cancer	0.000299	0.000585	CcSEcCtD
Moclobemide—MAOB—Metabolism—NAT2—urinary bladder cancer	0.000299	0.00118	CbGpPWpGaD
Moclobemide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000299	0.000584	CcSEcCtD
Moclobemide—Headache—Doxorubicin—urinary bladder cancer	0.000297	0.000581	CcSEcCtD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000283	0.00112	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CYP4B1—urinary bladder cancer	0.000282	0.00112	CbGpPWpGaD
Moclobemide—Nausea—Doxorubicin—urinary bladder cancer	0.000282	0.000551	CcSEcCtD
Moclobemide—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	0.000279	0.0011	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000275	0.00109	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000275	0.00109	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000273	0.00108	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000269	0.00107	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000269	0.00107	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—SLC19A1—urinary bladder cancer	0.000266	0.00105	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000262	0.00104	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000262	0.00104	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PRSS3—urinary bladder cancer	0.000259	0.00103	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—RRM2—urinary bladder cancer	0.000258	0.00102	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000257	0.00102	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	0.000256	0.00102	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000254	0.00101	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000253	0.001	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000253	0.001	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000251	0.000994	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—HPGDS—urinary bladder cancer	0.000239	0.000946	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—ENO2—urinary bladder cancer	0.000239	0.000946	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000236	0.000934	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000234	0.000928	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000234	0.000926	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000233	0.000925	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000233	0.000921	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—GSTT1—urinary bladder cancer	0.000232	0.000918	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000231	0.000913	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000229	0.000908	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000229	0.000908	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000223	0.000883	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000218	0.000865	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000218	0.000865	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000217	0.000861	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000217	0.000858	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000214	0.000849	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—TYMP—urinary bladder cancer	0.000207	0.000821	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.0002	0.000791	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000197	0.00078	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—NQO1—urinary bladder cancer	0.000193	0.000763	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—NAT2—urinary bladder cancer	0.000188	0.000743	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000184	0.000729	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	0.000171	0.000677	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	0.000162	0.000642	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—NAT1—urinary bladder cancer	0.000162	0.000642	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—RRM2—urinary bladder cancer	0.000162	0.000641	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—GSTP1—urinary bladder cancer	0.000161	0.000636	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000159	0.000631	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.000157	0.000623	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.000156	0.000617	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	0.000154	0.00061	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—HPGDS—urinary bladder cancer	0.00015	0.000594	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—ENO2—urinary bladder cancer	0.00015	0.000594	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—TYMS—urinary bladder cancer	0.000149	0.000591	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.000149	0.00059	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.000149	0.00059	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	0.000148	0.000587	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	0.000148	0.000585	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—NAT1—urinary bladder cancer	0.000148	0.000585	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—GSTM1—urinary bladder cancer	0.000148	0.000585	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—NCOR1—urinary bladder cancer	0.000148	0.000585	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GSTT1—urinary bladder cancer	0.000145	0.000576	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000145	0.000575	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—GPX1—urinary bladder cancer	0.000141	0.00056	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—ERCC2—urinary bladder cancer	0.000139	0.00055	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	0.000136	0.00054	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	0.000135	0.000535	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	0.000133	0.000528	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	0.000133	0.000527	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—MTHFR—urinary bladder cancer	0.00013	0.000517	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	0.000126	0.0005	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—NAT1—urinary bladder cancer	0.000126	0.0005	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	0.000126	0.000499	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000124	0.000492	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	0.000123	0.000486	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	0.000123	0.000486	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	0.000122	0.000482	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—NQO1—urinary bladder cancer	0.000121	0.000479	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—HRAS—urinary bladder cancer	0.000118	0.000467	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	0.000116	0.000459	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	0.000115	0.000457	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	0.000115	0.000455	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	0.000113	0.000447	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	0.000112	0.000443	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PPARG—urinary bladder cancer	0.000106	0.000419	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	0.000104	0.000412	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CREBBP—urinary bladder cancer	0.000102	0.000403	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GSTP1—urinary bladder cancer	0.000101	0.000399	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	9.84e-05	0.00039	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	9.82e-05	0.000389	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—TYMP—urinary bladder cancer	9.82e-05	0.000389	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	9.57e-05	0.000379	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	9.43e-05	0.000373	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—TYMS—urinary bladder cancer	9.37e-05	0.000371	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GSTM1—urinary bladder cancer	9.26e-05	0.000367	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—NCOR1—urinary bladder cancer	9.26e-05	0.000367	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—TYMP—urinary bladder cancer	9.03e-05	0.000358	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.98e-05	0.000356	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—TYMP—urinary bladder cancer	8.95e-05	0.000354	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—NAT2—urinary bladder cancer	8.88e-05	0.000352	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GPX1—urinary bladder cancer	8.87e-05	0.000351	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—ERCC2—urinary bladder cancer	8.71e-05	0.000345	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	8.6e-05	0.00034	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PTGS2—urinary bladder cancer	8.32e-05	0.00033	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—MTHFR—urinary bladder cancer	8.19e-05	0.000324	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—NAT2—urinary bladder cancer	8.16e-05	0.000323	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—NAT2—urinary bladder cancer	8.09e-05	0.000321	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.67e-05	0.000304	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—RRM2—urinary bladder cancer	7.66e-05	0.000304	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—TYMP—urinary bladder cancer	7.65e-05	0.000303	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.35e-05	0.000291	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PTEN—urinary bladder cancer	7.26e-05	0.000287	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—ENO2—urinary bladder cancer	7.1e-05	0.000281	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	7.1e-05	0.000281	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	7.06e-05	0.000279	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—RRM2—urinary bladder cancer	7.05e-05	0.000279	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—RRM2—urinary bladder cancer	6.99e-05	0.000277	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—EP300—urinary bladder cancer	6.92e-05	0.000274	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—NAT2—urinary bladder cancer	6.92e-05	0.000274	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	6.88e-05	0.000273	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.78e-05	0.000268	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PPARG—urinary bladder cancer	6.64e-05	0.000263	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—ENO2—urinary bladder cancer	6.53e-05	0.000259	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	6.53e-05	0.000259	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	6.47e-05	0.000256	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—ENO2—urinary bladder cancer	6.47e-05	0.000256	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.43e-05	0.000255	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CREBBP—urinary bladder cancer	6.38e-05	0.000253	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	6.33e-05	0.000251	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	6.28e-05	0.000249	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.18e-05	0.000245	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—RRM2—urinary bladder cancer	5.97e-05	0.000236	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—NQO1—urinary bladder cancer	5.72e-05	0.000227	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.55e-05	0.00022	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—ENO2—urinary bladder cancer	5.53e-05	0.000219	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	5.53e-05	0.000219	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.5e-05	0.000218	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	5.36e-05	0.000212	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.28e-05	0.000209	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—NQO1—urinary bladder cancer	5.26e-05	0.000208	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PTGS2—urinary bladder cancer	5.22e-05	0.000207	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—NQO1—urinary bladder cancer	5.22e-05	0.000207	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.06e-05	0.0002	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.84e-05	0.000192	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	4.77e-05	0.000189	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.62e-05	0.000183	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PTEN—urinary bladder cancer	4.55e-05	0.00018	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—NQO1—urinary bladder cancer	4.46e-05	0.000177	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—TYMS—urinary bladder cancer	4.44e-05	0.000176	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.41e-05	0.000175	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	4.39e-05	0.000174	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	4.38e-05	0.000174	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	4.38e-05	0.000174	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	4.35e-05	0.000172	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—EP300—urinary bladder cancer	4.34e-05	0.000172	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.32e-05	0.000171	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.21e-05	0.000167	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GPX1—urinary bladder cancer	4.2e-05	0.000166	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	4.12e-05	0.000163	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—TYMS—urinary bladder cancer	4.08e-05	0.000162	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—TYMS—urinary bladder cancer	4.04e-05	0.00016	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	4.03e-05	0.00016	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	4.03e-05	0.00016	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	4e-05	0.000158	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	4e-05	0.000158	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	3.87e-05	0.000153	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GPX1—urinary bladder cancer	3.86e-05	0.000153	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GPX1—urinary bladder cancer	3.83e-05	0.000152	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	3.79e-05	0.00015	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.77e-05	0.000149	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	3.76e-05	0.000149	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	3.72e-05	0.000147	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.6e-05	0.000142	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	3.56e-05	0.000141	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	3.53e-05	0.00014	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—TYMS—urinary bladder cancer	3.46e-05	0.000137	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	3.42e-05	0.000135	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	3.42e-05	0.000135	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GPX1—urinary bladder cancer	3.27e-05	0.00013	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	3.21e-05	0.000127	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PPARG—urinary bladder cancer	3.14e-05	0.000124	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	3.02e-05	0.00012	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	3.02e-05	0.00012	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.89e-05	0.000114	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.86e-05	0.000113	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.78e-05	0.00011	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.75e-05	0.000109	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	2.47e-05	9.79e-05	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PPARG—urinary bladder cancer	2.45e-05	9.7e-05	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	2.35e-05	9.32e-05	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.27e-05	9e-05	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.25e-05	8.93e-05	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PTEN—urinary bladder cancer	2.16e-05	8.54e-05	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—EP300—urinary bladder cancer	2.06e-05	8.14e-05	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.98e-05	7.85e-05	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.97e-05	7.78e-05	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.93e-05	7.63e-05	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.89e-05	7.49e-05	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.87e-05	7.42e-05	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.68e-05	6.65e-05	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.6e-05	6.34e-05	CbGpPWpGaD
